Mitochondria-targeted peptide antioxidants: Novel neuroprotective agents
Journal Title: The AAPS Journal - Year 2006, Vol 8, Issue 3
Abstract
Increasing evidence suggests that mitochondrial dysfunction and oxidative stress play a crucial role in the majority of neurodegenerative diseases. Mitochondria are a major source of intracellular reactive oxygen species (ROS) and are particularly vulnerable to oxidative stress. Oxidative damage to mitochondria has been shown to impair mitochondrial function and lead to cell death via apoptosis and necrosis. Because dysfunctional mitochondria will produce more ROS, a feed-forward loop is set up whereby ROS-mediated oxidative damage to mitochondria favors more ROS generation, resulting in a vicious cycle. It is now appreciated that reduction of mitochondrial oxidative stress may prevent or slow down the progression of these neurodegenerative disorders. However, if mitochondria are the major source of intracellular ROS and mitochondria are most vulnerable to oxidative damage, then it would be ideal to deliver the antioxidant therapy to mitochondria. This review will summarize the development of a novel class of mitochondria-targeted antioxidants that can protect mitochondria against oxidative stress and prevent neuronal cell death in animal models of stroke, Parkinson’s disease, and amyotrophic lateral sclerosis.
Authors and Affiliations
Hazel H. Szeto
Keywords
Related Articles
- EP ID EP681809
- DOI 10.1208/aapsj080362
- Views 88
- Downloads 0
Summary Report of PQRI Workshop on Nanomaterial in Drug Products: Current Experience and Management of Potential Risks
At the Product Quality Research Institute (PQRI) Workshop held last January 14–15, 2014, participants from academia, industry, and governmental agencies involved in the development and regulation of nanomedicines...
Polymeric Nanocarriers for Transport Modulation across the Pulmonary Epithelium: Dendrimers, Polymeric Nanoparticles, and their Nanoblends
The online version of this article (doi:10.1208/s12248-014-9588-5) contains supplementary material, which is available to authorized users.
The pharmacokinetics of escitalopram in patients with hepatic impairment
The effect of hepatic impairment on the pharmacokinetics of escitalopram was determined by means of nonlinear mixed effect modeling, considering both the Child-Pugh classification (and its components) and cytochrome P450...
Microdialysis versus other techniques for the clinical assessment of in vivo tissue drug distribution
Quantification of target site pharmacokinetics (PK) is crucial for drug discovery and development. Clinical micro-dialysis (MD) has increasingly been employed for the description of drug distribution and receptor phase P...
Multiple molecular targets in cancer chemoprevention by curcumin
Carcinogenesis encompasses 3 closely associated stages: initiation, progression, and promotion. Phytochemicals are nonnutritive components of plants that are currently being studied in chemoprevention of various diseases...